These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 742083)

  • 1. [Randomized study: chemotherapy versus chemotherapy plus transfer factor in metastasized breast neoplasm].
    Rainer H; Moser K; Bettelheim P
    Verh Dtsch Ges Inn Med; 1978; (84):604-6. PubMed ID: 742083
    [No Abstract]   [Full Text] [Related]  

  • 2. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.
    Andersson M; Daugaard S; von der Maase H; Mouridsen HT
    Cancer Treat Rep; 1986 Oct; 70(10):1181-6. PubMed ID: 3530444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin in the treatment of advanced breast cancer; comparative studies of three combination chemotherapy regimes.
    Brown I; Ward HW
    Clin Oncol; 1976 Jun; 2(2):105-11. PubMed ID: 954258
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinicopathological evaluation of preoperative chemotherapy with doxorubicin plus cyclophosphamide followed by paclitaxel for locally advanced breast cancer].
    Miyake T; Miyahara S; Fujii K; Taniguchi M; Yamamura K; Tadokoro K; Tanimura M; Nakamura H
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):401-5. PubMed ID: 19295263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
    Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF). Pilot study.
    Pannuti F; Rossi AP; Di Marco AR; Fruet F; Lelli G; Strocchi E; Rocchetta G; Piana E; Martoni A
    Panminerva Med; 1981; 23(1):25-8. PubMed ID: 7290722
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
    Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
    J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of breast cancer.
    Mitchell MS
    Conn Med; 1975 Jan; 39(1):4-5. PubMed ID: 1109851
    [No Abstract]   [Full Text] [Related]  

  • 10. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B.
    Hurd DD; Peters WP
    J Natl Cancer Inst Monogr; 1995; (19):41-4. PubMed ID: 7577204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery.
    De Lena M; Varini M; Zucali R; Rovini D; Viganotti G; Valagussa P; Veronesi U; Bonadonna G
    Cancer Clin Trials; 1981; 4(3):229-36. PubMed ID: 7026073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of combination of cyclophosphamide, adriamycin and platinum (CAP) versus cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in metastatic breast cancer.
    Tzekova V; Velikova M; Koynov K; Micheva D; Donchev T
    Neoplasma; 1991; 38(6):603-7. PubMed ID: 1766485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Supportive therapy with xenogenous peptides in patients with metastatic breast cancer undergoing aggressive chemotherapy (modified AC-protocol): a prospective, randomized double-blind study].
    Lange OF
    Onkologie; 1987 Jun; 10(3 Suppl):40-3. PubMed ID: 3309762
    [No Abstract]   [Full Text] [Related]  

  • 15. Case 3: infiltrating ductal breast carcinoma.
    Peoples GE; Arciero C; Adair C; Shriver CD;
    Oncology (Williston Park); 2004 Apr; 18(4):437-8, 440. PubMed ID: 15134352
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations.
    Smalley RV; Bartolucci AA
    Eur J Cancer (1965); 1980; Suppl 1():141-6. PubMed ID: 7318861
    [No Abstract]   [Full Text] [Related]  

  • 18. Polychemotherapeutic treatment of patients with metastatic breast cancer.
    Balázs M; Tüske M
    Acta Med Hung; 1986; 43(4):407-11. PubMed ID: 3601586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Buchholz TA; Tu X; Ang KK; Esteva FJ; Kuerer HM; Pusztai L; Cristofanilli M; Singletary SE; Hortobagyi GN; Sahin AA
    Cancer; 2005 Aug; 104(4):676-81. PubMed ID: 15981280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
    Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
    Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.